AstraZeneca reports strong Q1 growth and reiterates full-year guidance
Pharmaceutical giant AstraZeneca (AZN) made a strong start to 2022, reporting first quarter revenues up 60% to $11.39 billion and core EPS up 20% to $1.89.The increase in revenues was due to growth across the company's drug...
29 April 2022
